Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Effects of inhaled Seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)

Tuesday, January 2, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the effects of inhaled Seralutinib on right ventricular-pulmonary arterial coupling and right heart function in patients with pulmonary arterial hypertension (PAH). The findings suggest that Seralutinib may improve these cardiovascular parameters, indicating its potential as a therapeutic option for PAH. Further studies may be needed to confirm these results.
Price reaction · baseline $0.9125 (2023-12-29 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
+6.3%
day 1 · peak
+9.5%
day 3
-6.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Inhaled Seralutinib shows promise in improving RV-PA coupling.
  • Potential benefits for patients with pulmonary arterial hypertension.
  • Encouraging results for right heart function enhancement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Effects of inhaled Seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib?

Seralutinib is a treatment being studied for its effects on pulmonary arterial hypertension.

How does Seralutinib affect right heart function?

Inhaled Seralutinib may improve right ventricular-pulmonary arterial coupling and overall heart function.

What condition is Seralutinib targeting?

Seralutinib is targeting pulmonary arterial hypertension (PAH).

What are the potential benefits of Seralutinib?

It shows promise in enhancing cardiovascular parameters in PAH patients.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib PAH right heart function RV-PA coupling pulmonary arterial hypertension
Last updated: Jan 2, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →